Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 26.5
(1.73%)
SEK 26.5
(1.73%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -169.81 Million SEK | -42.7% |
| 2022 | -122.12 Million SEK | -39.06% |
| 2021 | -87.82 Million SEK | -95.91% |
| 2020 | -50.99 Million SEK | -9.6% |
| 2019 | -40.9 Million SEK | -116.5% |
| 2018 | -19.07 Million SEK | -57.02% |
| 2017 | -12.65 Million SEK | -256.71% |
| 2016 | -3.39 Million SEK | 70.62% |
| 2015 | -11.48 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -64.63 Million SEK | -25.0% |
| 2024 Q2 | -51.46 Million SEK | 21.24% |
| 2023 FY | - SEK | -64.28% |
| 2023 Q3 | -36.59 Million SEK | 28.03% |
| 2023 Q1 | -34.82 Million SEK | 34.03% |
| 2023 Q2 | -50.84 Million SEK | -45.99% |
| 2023 Q4 | -54.02 Million SEK | -47.64% |
| 2022 FY | - SEK | -39.06% |
| 2022 Q4 | -52.79 Million SEK | -101.17% |
| 2022 Q2 | -26.47 Million SEK | -59.36% |
| 2022 Q3 | -26.24 Million SEK | 0.88% |
| 2022 Q1 | -16.61 Million SEK | 66.54% |
| 2021 Q1 | -11.95 Million SEK | 8.33% |
| 2021 FY | - SEK | -95.91% |
| 2021 Q2 | -14.63 Million SEK | -22.41% |
| 2021 Q3 | -11.58 Million SEK | 20.87% |
| 2021 Q4 | -49.64 Million SEK | -328.67% |
| 2020 Q4 | -13.04 Million SEK | -35.45% |
| 2020 FY | - SEK | -9.6% |
| 2020 Q3 | -9.63 Million SEK | 28.25% |
| 2020 Q2 | -13.42 Million SEK | -55.68% |
| 2020 Q1 | -8.62 Million SEK | 44.77% |
| 2019 Q2 | -8.87 Million SEK | -31.69% |
| 2019 Q1 | -6.74 Million SEK | 17.25% |
| 2019 Q3 | -8.44 Million SEK | 4.9% |
| 2019 FY | - SEK | -116.5% |
| 2019 Q4 | -15.6 Million SEK | -84.92% |
| 2018 Q4 | -8.14 Million SEK | -138.65% |
| 2018 Q1 | -1.32 Million SEK | 66.03% |
| 2018 FY | - SEK | -57.02% |
| 2018 Q2 | -6.07 Million SEK | -357.41% |
| 2018 Q3 | -3.41 Million SEK | 43.86% |
| 2017 Q4 | -3.91 Million SEK | -69.64% |
| 2017 Q1 | -6.16 Million SEK | -161.59% |
| 2017 Q2 | 894 Thousand SEK | 114.5% |
| 2017 FY | - SEK | -256.71% |
| 2017 Q3 | -2.3 Million SEK | -357.94% |
| 2016 Q1 | -3.41 Million SEK | 0.0% |
| 2016 FY | - SEK | 70.62% |
| 2016 Q3 | -6.56 Million SEK | -92.26% |
| 2016 Q4 | 10.01 Million SEK | 252.62% |
| 2016 Q2 | -3.41 Million SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | -659.357% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 46.509% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 39.789% |
| Xintela AB (publ) | -53.47 Million SEK | -217.583% |
| Active Biotech AB (publ) | -43.88 Million SEK | -286.937% |
| Amniotics AB (publ) | -27.14 Million SEK | -525.631% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -1094.45% |
| BioArctic AB (publ) | 275.38 Million SEK | 161.664% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 53.83% |
| Camurus AB (publ) | 562.54 Million SEK | 130.187% |
| Cantargia AB (publ) | -284.31 Million SEK | 40.272% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -767.332% |
| CombiGene AB (publ) | -35.33 Million SEK | -380.571% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -20.564% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -893.971% |
| Genovis AB (publ.) | 64.57 Million SEK | 362.986% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -47.785% |
| Mendus AB (publ) | -97.84 Million SEK | -73.553% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -358.662% |
| Intervacc AB (publ) | -68.98 Million SEK | -146.18% |
| Kancera AB (publ) | -61.88 Million SEK | -174.386% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -534.04% |
| LIDDS AB (publ) | -39.67 Million SEK | -328.069% |
| Lipum AB (publ) | -37.11 Million SEK | -357.488% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -1302.966% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 640.743% |
| NextCell Pharma AB | -40.98 Million SEK | -314.333% |
| OncoZenge AB (publ) | 7.26 Million SEK | 2437.118% |
| Saniona AB (publ) | -69.69 Million SEK | -143.654% |
| Ziccum AB (publ) | -20.34 Million SEK | -734.8% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 8490850.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 28.533% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -8064.183% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -1164.351% |
| Corline Biomedical AB | -1.69 Million SEK | -9942.283% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 2.025% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -209.847% |
| Aptahem AB (publ) | -10 Million SEK | -1596.585% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 1570.387% |
| Fluicell AB (publ) | -25.91 Million SEK | -555.302% |
| Biovica International AB (publ) | -119.5 Million SEK | -42.097% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -302.176% |
| AcouSort AB (publ) | -16.7 Million SEK | -916.674% |
| Abliva AB (publ) | -93.6 Million SEK | -81.411% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 46.783% |
| 2cureX AB (publ) | -35.13 Million SEK | -383.308% |
| I-Tech AB | 30.34 Million SEK | 659.614% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 76.235% |
| Cyxone AB (publ) | -20.41 Million SEK | -731.856% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -65.749% |
| Biosergen AB | 228 Thousand SEK | 74580.263% |
| Nanologica AB (publ) | -62.11 Million SEK | -173.37% |
| SynAct Pharma AB | -222.7 Million SEK | 23.748% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -287.166% |
| BioInvent International AB (publ) | -312.7 Million SEK | 45.695% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 54982.956% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 404431.056% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 26.684% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -1826.984% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -56.428% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -1380.643% |